Physician profile
Charles A Mathis
NPI 1326042029
$13,073.54
in general payments reported to CMS, 2019-2025
43 companies · $852 in 2025
The $852 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,667 · 2020: $1,725 · 2021: $2,489 · 2022: $2,412 · 2023: $1,815 · 2024: $2,114 · 2025: $852.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,781.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,780.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,878.04 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $1,740.61 | 2019-2025 | |
| Amgen INC. | $969.76 | 2019-2024 | Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $824.01 | 2019-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $790.71 | 2021-2025 | Verquvo, Capvaxive |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $657.33 | 2019-2025 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $646.24 | 2019-2025 | Camzyos, Eliquis |
| Pfizer INC. | $617.87 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $499.39 | 2019-2023 | Brilinta, Farxiga |
| Esperion Therapeutics, INC. | $489.82 | 2020-2025 | Nexletol |
| Alnylam Pharmaceuticals INC. | $482.63 | 2020-2025 | Onpattro |
| Bayer Healthcare Pharmaceuticals INC. | $464.38 | 2021-2024 | |
| Sanofi-Aventis U.S. LLC | $451.81 | 2019-2024 | |
| Boston Scientific Corporation | $344.74 | 2022-2025 | Watchman Access System, Watchman Flx, Cds - Mct/Cem Monitoring |
| Chiesi USA, INC. | $283.41 | 2020-2024 | Cleviprex, Kengreal |
Show all 42 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Mathis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.